Shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) have been given an average recommendation of “Hold” by the eight brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $2.01.
HCAT has been the topic of several recent analyst reports. Wells Fargo & Company cut their price objective on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th. Canaccord Genuity Group cut shares of Health Catalyst from a “buy” rating to a “hold” rating and decreased their target price for the stock from $3.00 to $1.80 in a report on Thursday, August 20th. Citigroup dropped their target price on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Health Catalyst in a report on Monday.
View Our Latest Stock Analysis on HCAT
Insider Buying and Selling
In other news, CEO Simeon Kohl acquired 59,000 shares of the stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $1.79 per share, for a total transaction of $105,610.00. Following the transaction, the chief executive officer owned 2,856,385 shares in the company, valued at approximately $5,112,929.15. This trade represents a 2.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 19.40% of the company’s stock.
Institutional Trading of Health Catalyst
Several hedge funds and other institutional investors have recently modified their holdings of HCAT. Visionary Wealth Advisors purchased a new position in Health Catalyst during the 2nd quarter valued at about $27,000. AXQ Capital LP acquired a new position in shares of Health Catalyst in the 2nd quarter valued at about $38,000. Deutsche Bank AG purchased a new stake in shares of Health Catalyst in the second quarter worth approximately $43,000. Perigon Wealth Management LLC purchased a new stake in shares of Health Catalyst in the second quarter worth approximately $77,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Health Catalyst during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 85.00% of the company’s stock.
Health Catalyst Price Performance
Shares of NASDAQ HCAT opened at $1.69 on Monday. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.70 and a current ratio of 2.70. The stock’s fifty day simple moving average is $1.72 and its 200 day simple moving average is $1.72. Health Catalyst has a 52-week low of $0.96 and a 52-week high of $3.36.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%. The business had revenue of $70.49 million during the quarter, compared to the consensus estimate of $69.09 million. As a group, sell-side analysts predict that Health Catalyst will post -0.18 earnings per share for the current year.
Health Catalyst Company Profile
Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.
The company’s offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.
See Also
- Five stocks we like better than Health Catalyst
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
